FILANA THERAPEUTICS, INC.

Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system disorders. The company's lead drug candidate is simufilam, a proprietary oral small molecule designed to modulate filamin A protein activity. Filana is studying simufilam specifically for the treatment of tuberous sclerosis complex-related epilepsy, a genetic condition that causes non-malignant tumors and frequent treatment-resistant seizures. While the company operates in pharmaceutical research and development, its prospective end users are individuals affected by central nervous system conditions and tuberous sclerosis complex.

The company is headquartered in Austin, Texas. Filana maintains exclusive worldwide rights and patent protections for simufilam across jurisdictions including the United States, Europe, Australia, Israel, Canada, and Japan. The company does not own or lease manufacturing facilities, choosing instead to outsource development, formulation, and drug substance production to third-party contract manufacturers such as Evonik Corporation. Research collaborations, preclinical evaluations, and patent licensing agreements have also been established with academic and scientific organizations.

Summary of the business section of Filana Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 17 full-time employees and 3 employees who devote a portion of their professional time to the Company.”